|
|
|
|
Barron's(7/6) Tech Trader: Marshalling Evi
Two government reports Tuesday offered early hints of the potential industry impact of a $1.1 billion federal program to compare the medical benefit and cost-effectiveness of surgeries, medicines and medical devices.The reports -- by the...
|
|
|
Update Module 1484: CVD Guide - Part 1
How does smoking harm the heart?In many ways: for example it interferes with blood oxygenation, increases blood pressure and the strain on blood vessels, while tar lines the lungs, reducing the area available for oxygen transfer? Why is...
|
|
|
Sanofi: FDA approved atrial fibrillation drug Multaq, first new arrhythmia drug in a decade
TRENTON, N.J.(AP) - Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago. Multaq is intended to...
|
|
|
Sanofi-Aventis arrhythmia drug Multaq approved
TRENTON, N.J.(AP) - Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago. Multaq is intended to...
|
|
|
FDA Approves Heart Drug After New Trials
WASHINGTON, July 2 -- The FDA has approved the antiarrhythmic dronedarone (Multaq) for treatment of atrial fibrillation and atrial flutter, the drug's developer announced today.Dronedarone is the first drug approved in the U.S. that has...
|
|
|
Sanofi-Aventis arrhythmia drug Multaq approved
NEW YORK - Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval after a delay of nearly three years.Multaq is intended to treat atrial flutter and atrial fibrillation, a...
|
|
|
Sanofi-Aventis arrhythmia drug Multaq approved
Sanofi says FDA approved atrial fibrillation drug Multaq, and plans launch for summer 2009 Buzz up!Companies: NEW YORK (AP) -- Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing...
|
|
|
Sanofi-Aventis arrhythmia drug Multaq approved
NEW YORK (AP) -- Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval after a delay of nearly three years.Multaq is intended to treat atrial flutter and atrial fibrillation, a...
|
|
|
Cordex Completes Production of ATPace Clinical Trial Material
Cordex Pharma, Inc.(OTC:CDXP) (BULLETIN BOARD: CDXP) announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials. The protocol of...
|
|
|
Incidence of Ventricular Arrhythmias in Patients on Long-term Support With a Continuous-flow Assist Device (He
Langford Lane, Kidlington Oxford.OX5 1GB UK Tel: +44 (0) 1865-843177 (Within Europe) Fax: +44 (0) 1865-843970 E-mail: eurosupport@elsevier.com North American and Rest of World Online Customer Service 6277 Sea Harbor Drive Orlando.
|
|
|
Cordex Completes Production of ATPace Drug Clinical Trial
Cordex Pharma said today it successfully completed the production of the ATPace clinical trial material (CTM) in preparation for planned pivotal clinical trials.ATPace is a novel, proprietary, stable, injectable formulation of adenosine 5...
|
|
|
Cordex completes production of ATPace Clinical Trial Material
Cordex Pharma, a specialty pharmaceutical company that develops new cardiovascular medicines has successfully completed the production of the ATPace clinical trial material (CTM) in preparation for planned pivotal clinical trials.The...
|
|
|
Cordex Completes Production Of ATPace Clinical Trial Material
Clinical trials for the acute treatment of patients presenting with paroxysmal supraventricular tachycardia (PSVT) Cordex has completed the production of the ATPace clinical trial material (CTM), in preparation for planned pivotal clinical...
|
|
|
CardioNet, Inc. Updates Full Year 2009 Guidance, Industry Dynamics and Future Strategies
Companies mentioned in this article: CardioNet, Inc.CONSHOHOCKEN, Pa. -- (BUSINESSWIRE) -- CardioNet (Nasdaq:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac ...
|
|
|
Biosense Webster To Showcase CARTO 3 System At EUROPACE
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase the CARTO 3 System, the most advanced three-dimensional imaging technology for use by electrophysiologists in treating...
|
|
|
Chemotherapy-Related Cardiac Toxicity Requires Mor
Orlando, Fla.-Modern chemotherapy often can cure cancer, but at a significant cost to the heart, according to a growing body of data showing life-long cardiomyopathy in many cancer survivors.Chemotherapy-related cardiotoxicity is gaining...
|
|
|
Study results from GlaxoSmithKline update understanding of life sciences
'Assessing the potential for a new drug to cause life-threatening arrhythmias is now an integral component of premarketing safety assessment.International Conference on Harmonization of Technical Requirements for Registration of...
|
|
|
Billy Mays: attention to the warning signs of heart disease for military veterans and civilians
Hardening of the arteries and heart weight of >500 grams indicative of hypertensive heart disease and left ventricular enlargement.Although Mr. Mays was prescrbed two different pain medications for hip pain (he was scheduled to...
|
|
|
New therapy found to prevent heart failure
A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who...
|
|
|
Cordex Pharma's ATPace Drug
Cordex Pharma said today it successfully completed the production of the ATPace clinical trial material (CTM) in preparation for planned pivotal clinical trials.ATPace is a novel, proprietary, stable, injectable formulation of adenosine 5...
|
|
|
Cordex Pharma Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials.
|
|
|
Sinus rhythm restoration by catheter ablation in patients with long-lasting atrial fibrillation and congestive
LVEF and NYHA class dramatically improved in 5 DCM pts NYHA class, but not LVEF, improved in ICM pt Redo ablative procedure in 4 pf 5 DCM pts and in ICM pt due to arrhythmia recurrence LVEF and NYHA improved in DCM pts, leading to ICD...
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials.
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials.
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif.ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic drug for the management of cardiac arrhythmias. A stable...
|
